Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621001476820
Ethics application status
Approved
Date submitted
4/08/2021
Date registered
28/10/2021
Date last updated
7/10/2022
Date data sharing statement initially provided
28/10/2021
Type of registration
Retrospectively registered

Titles & IDs
Public title
Measuring the effects of L-arginine and aged garlic extract on migraine in Australian adults
Scientific title
Investigating the effects of L-arginine and aged garlic extract on frequency and severity of migraine in adults
Secondary ID [1] 304805 0
Nil known
Universal Trial Number (UTN)
U1111-1268-1117
Trial acronym
L-Arginine and Garlic Extract trial (the LARGE-trial)
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Migraine 322868 0
Condition category
Condition code
Neurological 320449 320449 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
We compare L-arginine and aged garlic extract (AGE) as separate systemic vasodilating agents to see which (if either) is more effective in preventing migraines. We assess whether any of these comparators have differing efficacies in different aspects of the headache, such as frequency, duration or severity. Each subject will self-administer the treatments as follows: 2500 mg/day placebo as oral capsules for the first 2 weeks, then their allocated treatment (placebo oral capsules, 1500 mg/day L-arginine oral capsules, 1000 mg/day AGE oral capsules, or both as oral capsules) for the next 12 weeks. Participants are required to return the initial capsule bottle (placebo capsules provided at week 1) at the baseline visit (week 3). Eighty percent compliance is required to continue in the study to ensure compliance during treatment. Participants are also contacted one week following commencement of treatment to discuss any potential adverse events and treatment compliance. Participants are required to return their treatment capsule bottle(s) at the end of week 14 (post-intervention) visit to monitor adherence.
Intervention code [1] 321178 0
Treatment: Other
Comparator / control treatment
We include a placebo control to see whether the two compounds do have a significant effect on migraines. The placebo treatment is comprised of microcellulose capsules
Control group
Placebo

Outcomes
Primary outcome [1] 328348 0
To measure the effects of 1500 mg/day L-arginine and/or 1000 mg/day aged garlic extract (AGE) on migraine frequency in migraineurs, over 14 weeks
Measured via daily headache diaries
Timepoint [1] 328348 0
Daily over the 14 weeks
Primary outcome [2] 328349 0
To measure the effects of 1500 mg/day L-arginine and/or 1000 mg/day aged garlic extract (AGE) on photosensitivity in migraineurs, over 14 weeks
Measured via photosensitivity test
Timepoint [2] 328349 0
At Weeks 3 (baseline) and 14 (immediate post-intervention)
Primary outcome [3] 328350 0
To measure the effects of 1500 mg/day L-arginine and/or 1000 mg/day aged garlic extract (AGE) on quality of life in migraineurs, over 14 weeks
Measured via Migraine-Specific Quality-of-Life Questionnaire (MSQ)
Timepoint [3] 328350 0
At Weeks 1 (pre-baseline) and 14 (immediate post-intervention)
Secondary outcome [1] 398681 0
To measure the effects of 1500 mg/day L-arginine and/or 1000 mg/day aged garlic extract (AGE) on retinal vascular diameter in migraineurs, over 12 weeks
Measured via optical coherence tomography angiography (OCTA) scans of left and right eyes
Timepoint [1] 398681 0
At Weeks 3 (baseline) and 14 (immediate post-intervention)
Secondary outcome [2] 398682 0
To examine the adverse effects of 1500 mg/day L-arginine and/or 1000 mg/day aged garlic extract (AGE) on the body in migraineurs, over 14 weeks
Examined via reporting of quantity and quality of adverse effects by participants and graded according to the NCI-CTCAE v5 (or higher)
Timepoint [2] 398682 0
Daily reporting throughout 14-week duration of trial
Secondary outcome [3] 399867 0
Primary outcome: To measure the effects of 1500 mg/day L-arginine and/or 1000 mg/day aged garlic extract (AGE) on migraine severity in migraineurs, over 14 weeks
Measured using the Short-Form McGill Pain Questionnaire (SF-MPQ)
Timepoint [3] 399867 0
At Weeks 1 (pre-baseline), 14 (immediate post-intervention) and weekly over the 14 weeks.
Secondary outcome [4] 400404 0
Primary outcome: To measure the effects of 1500 mg/day L-arginine and/or 1000 mg/day aged garlic extract (AGE) on photosensitivity in migraineurs, over 14 weeks using the Visual Light Sensitivity Questionnaire – 8 (VLSQ-8)
Timepoint [4] 400404 0
At weeks 1 (pre-baseline) and 14 (immediate post-intervention)
Secondary outcome [5] 400405 0
Primary outcome: To measure the effects of 1500 mg/day L-arginine and/or 1000 mg/day aged garlic extract (AGE) on photosensitivity in migraineurs, over 14 weeks as measured by the Leiden Visual Sensitivity Scale (L-VISS)
Timepoint [5] 400405 0
At weeks 1 (pre-baseline) and 14 (immediate post-intervention)
Secondary outcome [6] 400457 0
Primary outcome: To measure the effects of 1500 mg/day L-arginine and/or 1000 mg/day aged garlic extract (AGE) on migraine severity in migraineurs, over 14 weeks
Measured via daily headache diaries
Timepoint [6] 400457 0
Daily over the 14 weeks
Secondary outcome [7] 400468 0
To measure the effects of 1500 mg/day L-arginine and/or 1000 mg/day aged garlic extract (AGE) on blood biomarkers of vascular tone in migraineurs, over 12 weeks
Measured via enzyme-linked immunological assay (ELISA) for asymmetric dimethylarginine (ADMA)
Timepoint [7] 400468 0
Fasted blood samples collected at Weeks 3 (baseline) and 14 (immediate post-intervention) will be analysed
Secondary outcome [8] 400469 0
To measure the effects of 1500 mg/day L-arginine and/or 1000 mg/day aged garlic extract (AGE) on blood biomarkers of vascular tone in migraineurs, over 12 weeks
Measured via enzyme-linked immunological (ELISA) assay for symmetric dimethylarginine (SDMA)
Timepoint [8] 400469 0
Fasted blood samples collected at Weeks 3 (baseline) and 14 (immediate post-intervention) will be analysed
Secondary outcome [9] 400470 0
To measure the effects of 1500 mg/day L-arginine and/or 1000 mg/day aged garlic extract (AGE) on blood biomarkers of vascular tone in migraineurs, over 12 weeks
Measured via enzyme-linked immunological assay (ELISA) for nitrites and nitrates
Timepoint [9] 400470 0
Fasted blood samples collected at Weeks 3 (baseline) and 14 (immediate post-intervention) will be analysed
Secondary outcome [10] 400471 0
To measure the effects of 1500 mg/day L-arginine and/or 1000 mg/day aged garlic extract (AGE) on blood biomarkers of vascular tone in migraineurs, over 12 weeks
Measured via enzyme-linked immunological assay (ELISA) for endothelin-1
Timepoint [10] 400471 0
Fasted blood samples collected at Weeks 3 (baseline) and 14 (immediate post-intervention) will be analysed

Eligibility
Key inclusion criteria
1. Migraine (with or without aura) diagnosed at least 1 year ago
2. Migraine onset occurred before 50 years of age
3. 2-6 migraine episodes and fewer than 6 'other' headache types per month, over the last 3 months
4. Able to distinguish between migraine and 'other' headache types
5. Able to complete a daily diary about migraine experience
6. Able to commit to taking the 5 capsules a day for 14 weeks
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Taking medications/drugs affecting vascular tone or blood pressure
2. Taking nitrate drugs or isoproterenol (often prescribed for angina or heart failure)
3. Taking more than two migraine-prevention drugs
4. Taking antidepressants or diuretics, herbs, supplements
5. Taking Sildafenil, Cialis, Spedra and any other PGE-5 inhibitor drugs
6. Taking drugs with potential blood-vessel effects (analgesics, decongestants, or antihistamines)
7. Already taking L-arginine or garlic supplements for 3 months before the study
8. Having headaches causing fainting or another medical emergency
9. Having chronic daily headaches, medication-overuse headaches and/or other secondary headache disorders
10. Having diagnoses other than migraine as the primary cause of headache
11. A change in migraine treatment in the 3 months prior to or during the study
12. Clinical reports of renal or liver dysfunction
13. Clinical risks associated with bleeding or coagulopathy or currently on blood-thinning medications such as warfarin/heparin therapy
14. Having any cardiovascular or neoplastic diseases
15. Having major chronic metabolic or neurologic disorders, or receiving current therapy for them
16. Being diagnosed with psychosis or bipolar affective disorder
17. Diagnosis of cancer
18. Substance abuse/dependence/addiction in the 3 months prior to or during the study
19. Having an history of diabetes, hypertension, collagen vascular disease, vasculitis, or renal disease/failure
20. Having any low-blood-pressure-related issues or Type-1 or -2 diabetes
21. Having the possibility of pregnancy or lactation
22. Being allergic to garlic or its constituents
23. Having gastric disturbances such as bloating, stomach pain, heartburn, diarrhoea, constipation, nausea or vomiting
24. Are a smoker
25. Having an history of eye pathology, surface disorder, surgery (except cataract extraction), injury
26. Not being able to see clearly (with glasses, if need be)
27. Having disorders of the optic nerve (including glaucoma) or retina
28. The significant possibility of our not being able to see the inside of your eye clearly
29. Having poor image perception due to cataract or unstable fixation

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The statistician will allocate an identification number to each participant, as per the IHS guidelines. They will do this after the investigator enters the participants into the REsearch Data Capture (REDCap) tool, whereby the statistician will then have access to the list and be able to assign identification numbers that the investigators will not be privy to.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
We are using block randomisation: eligible subjects will be computer-randomised in blocks of 8, to one of the 4 treatment groups (placebo control, L-arginine, aged garlic extract (AGE), and L-arginine + AGE). As migraine is taken to be specifically affected by hormonal cyclical changes, we aim to control for menstruation effects in our statistical analysis. We will randomise by participant ID, as this should preclude group allocation by order of study entry.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
We will analyse the results at the completion of the trial, using IBM SPSS® Statistics for Windows, Version 24.0 (IBM Corp., Armonk NY, USA). We will analyse data on an intention-to-treat basis if at least two months of the headache diary are completed. If data from the final (third) trial month is missing, we will substitute in data from the second month. We will report results as a group mean ± standard deviation (SD). We will analyse differences in outcome measures within the groups using Wilcoxon’s matched-pairs signed-ranks test, and we will analyse outcome differences between the groups using the Mann-Whitney U test. We will use the Chi-Square test for demographic data. The criterion for statistical significance will be p < 0.05. We will organise the 4 randomised treatment groups as sex-by-treatment as a 2x2 factorial. We will analyse data from continuous variable outcomes using a General Linear Model, with the baseline values as covariates. We will conduct a post-hoc comparison of means if the interaction between sex and treatment is statistically significant. We will express differences between treatment groups as mean differences with associated 95% confidence intervals. We will analyse data from categorical variable outcomes using a Multivariable Logistic Regression Model, again with the baseline values as covariates. We will express treatment group effects as odds ratios with associated 95% confidence intervals. We will examine residuals from the analyses.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
27/05/2021
Date of last participant enrolment
Anticipated
30/06/2023
Actual
Date of last data collection
Anticipated
6/10/2023
Actual
Sample size
Target
240
Accrual to date
90
Final
Recruitment in Australia
Recruitment state(s)
WA

Funding & Sponsors
Funding source category [1] 309175 0
Charities/Societies/Foundations
Name [1] 309175 0
Multiple Sclerosis WA (MSWA)
Country [1] 309175 0
Australia
Funding source category [2] 309588 0
Charities/Societies/Foundations
Name [2] 309588 0
The McCusker Charitable Foundation
Country [2] 309588 0
Australia
Primary sponsor type
University
Name
Curtin University
Address
Kent Street, Bentley WA 6102
Country
Australia
Secondary sponsor category [1] 310580 0
None
Name [1] 310580 0
None
Address [1] 310580 0
None
Country [1] 310580 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 309035 0
Curtin University Human Research Ethics Committee (HREC)
Ethics committee address [1] 309035 0
Ethics committee country [1] 309035 0
Australia
Date submitted for ethics approval [1] 309035 0
Approval date [1] 309035 0
19/04/2021
Ethics approval number [1] 309035 0
HRE2020-0466

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 112730 0
Prof John Mamo
Address 112730 0
Curtin University, Kent Street, Bentley WA 6102
Country 112730 0
Australia
Phone 112730 0
+61 08 9266 7232
Fax 112730 0
Email 112730 0
[email protected]
Contact person for public queries
Name 112731 0
John Mamo
Address 112731 0
Curtin University, Kent Street, Bentley WA 6102
Country 112731 0
Australia
Phone 112731 0
+61 08 9266 7232
Fax 112731 0
Email 112731 0
[email protected]
Contact person for scientific queries
Name 112732 0
John Mamo
Address 112732 0
Curtin University, Kent Street, Bentley WA 6102
Country 112732 0
Australia
Phone 112732 0
+61 08 9266 7232
Fax 112732 0
Email 112732 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseL-arginine and aged garlic extract for the prevention of migraine: a study protocol for a randomised, double-blind, placebo-controlled, phase-II trial (LARGE trial).2023https://dx.doi.org/10.1186/s12883-023-03149-y
N.B. These documents automatically identified may not have been verified by the study sponsor.